# Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs

> **NCT01475851** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 34 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** GSK548470 300 mg tablet

## Key facts

- **NCT ID:** NCT01475851
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-06
- **Final completion:** 2014-10
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2015-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01475851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01475851, "Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01475851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*